샘플 요청 목록

 카트 문의
시장보고서
상품코드
1866587

세계의 이중특이성 항체 요법 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)

Bi-Specific Antibodies Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
발행일: | 리서치사: QYResearch | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 이중특이성 항체 요법 시장 규모는 2024년에 41억 6,500만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 23.4%로 성장하여 2031년까지 180억 5,600만 달러로 확대될 것으로 예측됩니다.

이중특이성 항체(BsAb) 또는 이중특이성 단클론항체(BsMAb)는 두 종류의 서로 다른 항체 조각으로 구성된 인공 단백질입니다. 두 개의 서로 다른 항원 결합 영역을 포함하는 특성으로 인해 이중특이성 항체는 두 종류의 서로 다른 항원, 또는 하나의 항원에 두 개의 서로 다른 에피토프를 인식하고 결합할 수 있습니다.

이중특이성 항체 요법 시장의 성장은 임상 수요 증가, 기술 발전, 투자 모멘텀, 규제 지원 등의 요인이 복합적으로 작용하고 있습니다. 주요 촉진요인 중 하나는 전 세계적으로 증가하고 있는 암(특히 혈액 악성 종양 및 치료 저항성 고형 종양)의 발생률이며, 이로 인해 보다 정밀하고 효과적인 면역요법에 대한 강력한 수요가 발생하고 있습니다. 이중특이성 항체는 두 개의 서로 다른 항원을 동시에 표적으로 삼는 능력으로 특이성과 면역 활성화를 강화하여 종양학에서 유망한 차세대 치료 접근법으로 자리매김하고 있습니다.

생명공학 및 항체공학의 발전으로 이중특이성 항체 플랫폼의 개발이 크게 가속화되었습니다. 기존에는 구조적 복잡성, 낮은 안정성, 낮은 제조 수율 등의 문제로 인해 개발 진전이 제한적이었습니다. 그러나 단백질 설계, 발현 시스템, 약물전달 기술의 혁신으로 BiTE(이특이적 T세포 엔게이지), CrossMab, DVD-Ig와 같은 임상적으로 실용화 가능한 포맷이 등장했습니다. 이러한 혁신은 제조 가능성, 안정성, 유효성을 향상시켜 보다 광범위한 임상 파이프라인의 토대를 마련했습니다.

이와 함께 바이오의약품 분야의 투자자들의 관심과 자금 조달이 증가하면서 이중특이성 항체의 연구개발 확대에 힘을 실어주고 있습니다. 기존 제약회사와 바이오테크 스타트업 모두 활발한 벤처 캐피털과 전략적 제휴에 힘입어 이 분야에 대한 투자를 늘리고 있습니다. FDA, EMA 등 규제 당국도 신규 생물학적 제제 심사에 있어 유연성을 보여 이중특이성 치료제의 개발 기간 단축과 시장 접근성 촉진에 기여하고 있습니다.

환자 측면에서는 기존 치료법에 비해 우수한 치료 성적을 제공하는 표적화된 맞춤치료에 대한 수용도가 높아지고 있습니다. 이중특이성 항체는 종종 표적 외 독성 감소와 면역 매개 종양 세포 사멸을 강화하여 임상 도입을 더욱 촉진하고 있습니다.

요약하면, 이중특이성 항체 요법 시장은 미충족 수요, 기술 성숙, 강력한 자금 지원, 우호적인 규제 환경 등의 요인으로 인해 빠르게 성장하고 있으며, 이러한 요인들이 복합적으로 작용하여 높은 잠재력을 가진 치료 영역으로 성장하고 있습니다.

세계 이중특이성 항체 요법의 주요 기업으로는 Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson 등이 있습니다. 세계 상위 5개 업체가 95% 이상의 점유율을 차지하고 있습니다. 북미가 가장 큰 시장으로 약 65%의 점유율을 차지하고 있으며, 유럽과 중국이 각각 30% 이상의 점유율을 차지하고 있습니다. 제품별로는 IgG 기반 항체가 가장 큰 부문으로 85% 이상의 점유율을 차지하고 있습니다. 용도별로는 혈우병이 가장 큰 용도이며, 그 다음으로 암 등이 그 뒤를 잇습니다.

이 보고서는 이중특이성 항체 요법 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

이중특이성 항체 요법의 시장 규모 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함하는 매출액으로 제시되어 있습니다. 정량적, 정성적 분석을 통해 독자들이 이중특이성 항체 요법 관련 사업 전략 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 자사 포지셔닝 분석, 정보에 입각한 사업적 판단을 할 수 있도록 지원합니다.

시장 세분화

기업별

  • Roche
  • Amgen
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • AbbVie
  • Lindis Biotech
  • MacroGenics, Inc
  • Genmab
  • Alphamab Co. Ltd
  • Akeso, Inc.

유형별 부문

  • 프래그먼트 기반 항체
  • IgG 기반 항체

용도별 부문

  • 암
  • 혈우병
  • 기타 비암 질환

지역별

  • 북미
    • 미국
    • 캐나다
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 동남아시아
    • 인도
    • 호주
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 네덜란드
    • 북유럽 국가
    • 기타 유럽
  • 라틴아메리카
    • 멕시코
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 튀르키예
    • 사우디아라비아
    • 아랍에미리트
    • 기타 중동 및 아프리카
KSM 25.11.26

자주 묻는 질문

  • 이중특이성 항체 요법 시장 규모는 어떻게 예측되나요?
  • 이중특이성 항체 요법의 주요 기업은 어디인가요?
  • 이중특이성 항체 요법 시장의 주요 성장 요인은 무엇인가요?
  • 이중특이성 항체의 주요 특징은 무엇인가요?
  • 이중특이성 항체 요법의 시장 세분화는 어떻게 이루어지나요?
  • 이중특이성 항체 요법의 주요 용도는 무엇인가요?
  • 이중특이성 항체 요법의 시장에서 북미의 점유율은 얼마인가요?

The global market for Bi-Specific Antibodies Therapy was estimated to be worth US$ 4165 million in 2024 and is forecast to a readjusted size of US$ 18056 million by 2031 with a CAGR of 23.4% during the forecast period 2025-2031.

A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.

The growth of the bispecific antibody therapy market is driven by a combination of rising clinical demand, technological advancements, investment momentum, and regulatory support. One of the primary drivers is the increasing global incidence of cancer-particularly hematological malignancies and treatment-resistant solid tumors-which has created a strong demand for more precise and effective immunotherapies. Bispecific antibodies, with their ability to simultaneously target two different antigens, offer enhanced specificity and immune activation, positioning them as a promising next-generation therapeutic approach in oncology.

Advancements in biotechnology and antibody engineering have significantly accelerated the development of bispecific platforms. Historically, challenges such as structural complexity, poor stability, and low manufacturing yield limited their progress. However, breakthroughs in protein design, expression systems, and drug delivery technologies have enabled the emergence of clinically viable formats such as BiTEs (bispecific T-cell engagers), CrossMabs, and DVD-Igs. These innovations have improved manufacturability, stability, and efficacy, paving the way for a broader clinical pipeline.

In parallel, growing investor interest and funding in the biopharmaceutical sector have fueled the expansion of bispecific antibody R&D. Both established pharmaceutical companies and biotech startups are increasingly investing in this field, supported by active venture capital and strategic partnerships. Regulatory bodies like the FDA and EMA are also showing flexibility in reviewing novel biologics, facilitating faster development timelines and market access for bispecific therapies.

On the patient side, there is increasing acceptance of targeted, personalized treatments that offer superior outcomes compared to traditional therapies. Bispecific antibodies often demonstrate reduced off-target toxicity and enhanced immune-mediated tumor cell killing, further driving clinical adoption.

In summary, the bispecific antibody therapy market is being propelled by unmet clinical needs, technological maturation, strong financial backing, and a favorable regulatory environment-factors that together are shaping a rapidly growing and high-potential therapeutic space.

Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%. North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.

This report aims to provide a comprehensive presentation of the global market for Bi-Specific Antibodies Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Bi-Specific Antibodies Therapy by region & country, by Type, and by Application.

The Bi-Specific Antibodies Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific Antibodies Therapy.

Market Segmentation

By Company

  • Roche
  • Amgen
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • AbbVie
  • Lindis Biotech
  • MacroGenics, Inc
  • Genmab
  • Alphamab Co. Ltd
  • Akeso, Inc.

Segment by Type

  • Fragment-Based Antibodies
  • IgG-Based Antibodies

Segment by Application

  • Cancer
  • Haemophilia
  • Other Non-Cancer Diseases

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Bi-Specific Antibodies Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Bi-Specific Antibodies Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Bi-Specific Antibodies Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Bi-Specific Antibodies Therapy Product Introduction
  • 1.2 Global Bi-Specific Antibodies Therapy Market Size Forecast (2020-2031)
  • 1.3 Bi-Specific Antibodies Therapy Market Trends & Drivers
    • 1.3.1 Bi-Specific Antibodies Therapy Industry Trends
    • 1.3.2 Bi-Specific Antibodies Therapy Market Drivers & Opportunity
    • 1.3.3 Bi-Specific Antibodies Therapy Market Challenges
    • 1.3.4 Bi-Specific Antibodies Therapy Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Bi-Specific Antibodies Therapy Players Revenue Ranking (2024)
  • 2.2 Global Bi-Specific Antibodies Therapy Revenue by Company (2020-2025)
  • 2.3 Key Companies Bi-Specific Antibodies Therapy Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Bi-Specific Antibodies Therapy Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Bi-Specific Antibodies Therapy
  • 2.6 Bi-Specific Antibodies Therapy Market Competitive Analysis
    • 2.6.1 Bi-Specific Antibodies Therapy Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Bi-Specific Antibodies Therapy Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific Antibodies Therapy as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Fragment-Based Antibodies
    • 3.1.2 IgG-Based Antibodies
  • 3.2 Global Bi-Specific Antibodies Therapy Sales Value by Type
    • 3.2.1 Global Bi-Specific Antibodies Therapy Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Bi-Specific Antibodies Therapy Sales Value, by Type (2020-2031)
    • 3.2.3 Global Bi-Specific Antibodies Therapy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Cancer
    • 4.1.2 Haemophilia
    • 4.1.3 Other Non-Cancer Diseases
  • 4.2 Global Bi-Specific Antibodies Therapy Sales Value by Application
    • 4.2.1 Global Bi-Specific Antibodies Therapy Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Bi-Specific Antibodies Therapy Sales Value, by Application (2020-2031)
    • 4.2.3 Global Bi-Specific Antibodies Therapy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Bi-Specific Antibodies Therapy Sales Value by Region
    • 5.1.1 Global Bi-Specific Antibodies Therapy Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Bi-Specific Antibodies Therapy Sales Value by Region (2020-2025)
    • 5.1.3 Global Bi-Specific Antibodies Therapy Sales Value by Region (2026-2031)
    • 5.1.4 Global Bi-Specific Antibodies Therapy Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.2.2 North America Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.3.2 Europe Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Bi-Specific Antibodies Therapy Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.5.2 South America Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.3.2 United States Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.4.2 Europe Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.5.2 China Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.6.2 Japan Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.7.2 South Korea Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.9.2 India Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Roche
    • 7.1.1 Roche Profile
    • 7.1.2 Roche Main Business
    • 7.1.3 Roche Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.1.4 Roche Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Roche Recent Developments
  • 7.2 Amgen
    • 7.2.1 Amgen Profile
    • 7.2.2 Amgen Main Business
    • 7.2.3 Amgen Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.2.4 Amgen Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Amgen Recent Developments
  • 7.3 Sanofi
    • 7.3.1 Sanofi Profile
    • 7.3.2 Sanofi Main Business
    • 7.3.3 Sanofi Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.3.4 Sanofi Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Sanofi Recent Developments
  • 7.4 Pfizer
    • 7.4.1 Pfizer Profile
    • 7.4.2 Pfizer Main Business
    • 7.4.3 Pfizer Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.4.4 Pfizer Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Pfizer Recent Developments
  • 7.5 Johnson & Johnson
    • 7.5.1 Johnson & Johnson Profile
    • 7.5.2 Johnson & Johnson Main Business
    • 7.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.5.4 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Johnson & Johnson Recent Developments
  • 7.6 AstraZeneca
    • 7.6.1 AstraZeneca Profile
    • 7.6.2 AstraZeneca Main Business
    • 7.6.3 AstraZeneca Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.6.4 AstraZeneca Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.6.5 AstraZeneca Recent Developments
  • 7.7 AbbVie
    • 7.7.1 AbbVie Profile
    • 7.7.2 AbbVie Main Business
    • 7.7.3 AbbVie Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.7.4 AbbVie Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.7.5 AbbVie Recent Developments
  • 7.8 Lindis Biotech
    • 7.8.1 Lindis Biotech Profile
    • 7.8.2 Lindis Biotech Main Business
    • 7.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.8.4 Lindis Biotech Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Lindis Biotech Recent Developments
  • 7.9 MacroGenics, Inc
    • 7.9.1 MacroGenics, Inc Profile
    • 7.9.2 MacroGenics, Inc Main Business
    • 7.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.9.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.9.5 MacroGenics, Inc Recent Developments
  • 7.10 Genmab
    • 7.10.1 Genmab Profile
    • 7.10.2 Genmab Main Business
    • 7.10.3 Genmab Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.10.4 Genmab Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Genmab Recent Developments
  • 7.11 Alphamab Co. Ltd
    • 7.11.1 Alphamab Co. Ltd Profile
    • 7.11.2 Alphamab Co. Ltd Main Business
    • 7.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.11.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Alphamab Co. Ltd Recent Developments
  • 7.12 Akeso, Inc.
    • 7.12.1 Akeso, Inc. Profile
    • 7.12.2 Akeso, Inc. Main Business
    • 7.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.12.4 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Akeso, Inc. Recent Developments

8 Industry Chain Analysis

  • 8.1 Bi-Specific Antibodies Therapy Industrial Chain
  • 8.2 Bi-Specific Antibodies Therapy Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Bi-Specific Antibodies Therapy Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Bi-Specific Antibodies Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제